{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:08:28Z","timestamp":1793696908980,"version":"4.5.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117303","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:13:28Z","timestamp":1787166808000},"page":"117303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Baricitinib ameliorates behavioral deficits and NLRP3-related neuroinflammation in a ketamine rat model of schizophrenia: Role of JAK2\/STAT3 and PI3K\/AKT\/mTOR signaling"],"prefix":"10.1016","volume":"188","author":[{"given":"Ali A.","family":"Albariqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia A.","family":"Nawwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weam W.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2026.117303_bb0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia-an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"10039","key":"10.1016\/j.intimp.2026.117303_bb0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117303_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuropharm.2017.11.045","article-title":"NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update","volume":"142","author":"Cadinu","year":"2018","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.intimp.2026.117303_bb0020","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2026.117303_bb0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0278-5846(03)00080-0","article-title":"Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia","volume":"27","author":"Becker","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.intimp.2026.117303_bb0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neuropharm.2009.06.002","article-title":"Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?","volume":"57","author":"Behrens","year":"2009","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.intimp.2026.117303_bb0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.intimp.2026.117303_bb0040","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.intimp.2026.117303_bb0045","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1016\/j.intimp.2026.117303_bb0050","doi-asserted-by":"crossref","DOI":"10.31083\/JIN27636","article-title":"Neuroinflammation in schizophrenia: an overview of evidence and implications for pathophysiology","volume":"24","author":"Ermakov","year":"2025","journal-title":"J. Integr. Neurosci."},{"key":"10.1016\/j.intimp.2026.117303_bb0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"M\u00fcller","year":"2015","journal-title":"Front. Neurosci."},{"issue":"11","key":"10.1016\/j.intimp.2026.117303_bb0060","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jnen\/nlae066","article-title":"Increased inflammasome protein expression identified in microglia from postmortem brains with schizophrenia","volume":"83","author":"Gober","year":"2024","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117303_bb0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13651501.2022.2106245","article-title":"Increased NLRP3 inflammasome expression in peripheral blood mononuclear cells of patients with schizophrenia: a case-control study","volume":"27","author":"Ozdamar","year":"2023","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"1","key":"10.1016\/j.intimp.2026.117303_bb0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12974-021-02295-9","article-title":"Blockade of the NLRP3\/caspase-1 axis attenuates ketamine-induced hippocampus pyroptosis and cognitive impairment in neonatal rats","volume":"18","author":"Zhang","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2026.117303_bb0075","article-title":"Fibroblast growth factor 9 as a potential biomarker for schizophrenia","volume":"13","author":"Li","year":"2022","journal-title":"Front. Psych."},{"key":"10.1016\/j.intimp.2026.117303_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122838","article-title":"Repositioning of baricitinib for management of memory impairment in ovariectomized\/D-galactose treated rats: a potential role of JAK2\/STAT3-PI3K\/AKT\/mTOR signaling pathway","volume":"351","author":"Hindam","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2026.117303_bb0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.117303_bb0090","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117303_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"issue":"9929","key":"10.1016\/j.intimp.2026.117303_bb0100","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","article-title":"Schizophrenia: an integrated sociodevelopmental-cognitive model","volume":"383","author":"Howes","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2026.117303_bb0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41582-023-00904-0","article-title":"Schizophrenia: from neurochemistry to circuits, symptoms and treatments","volume":"20","author":"Howes","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"13","key":"10.1016\/j.intimp.2026.117303_bb0110","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117303_bb0115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2017.1307899","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: a 52-week, randomized, single-blind, extension study","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117303_bb0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12974-019-1565-6","article-title":"Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro","volume":"16","author":"Gavegnano","year":"2019","journal-title":"J. Neuroinflammation"},{"issue":"8","key":"10.1016\/j.intimp.2026.117303_bb0125","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/rheumatology\/kead013","article-title":"Inhibitory effect of baricitinib on microglia and STAT3 in a region with a weak blood-brain barrier in a mouse model of rheumatoid arthritis","volume":"62","author":"Matsushita","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2026.117303_bb0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jpsychires.2024.08.014","article-title":"Sex difference alters the behavioral and cognitive performance in a rat model of schizophrenia induced by sub-chronic ketamine","volume":"178","author":"Samizadeh","year":"2024","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117303_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70101","article-title":"Combined metformin and Baricitinib therapy attenuates inflammation in STZ-induced diabetic rats via AMPK\/JAK-STAT pathway crosstalk","volume":"8","author":"Allahyari","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"key":"10.1016\/j.intimp.2026.117303_bb0140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s43094-026-00937-4","article-title":"Repurposing baricitinib and\/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1\/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models","volume":"12","author":"El-Hanboshy","year":"2026","journal-title":"Futur. J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2026.117303_bb0145","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.phymed.2012.07.004","article-title":"Cerebroprotective effect of Eclipta alba against global model of cerebral ischemia induced oxidative stress in rats","volume":"19","author":"Mansoorali","year":"2012","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2026.117303_bb0150","article-title":"Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases","volume":"91","author":"Tatem","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.intimp.2026.117303_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.706494","article-title":"Risperidone mitigates enhanced excitatory neuronal function and repetitive behavior caused by an ASD-associated mutation of SIK1","volume":"14","author":"Badawi","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.intimp.2026.117303_bb0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2021.02.086","article-title":"LF-rTMS ameliorates social dysfunction of FMR1\u2212\/\u2212 mice via modulating Akt\/GSK-3\u03b2 signaling","volume":"550","author":"Hou","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2026.117303_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00257-24","article-title":"Human-derived fecal microbiota transplantation alleviates social deficits of the BTBR mouse model of autism through a potential mechanism involving vitamin B6 metabolism","volume":"9","author":"Zheng","year":"2024","journal-title":"mSystems"},{"issue":"2","key":"10.1016\/j.intimp.2026.117303_bb0170","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nprot.2006.116","article-title":"Morris water maze: procedures for assessing spatial and related forms of learning and memory","volume":"1","author":"Vorhees","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.intimp.2026.117303_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110583","article-title":"Niacin mitigates blood-brain barrier tight junctional proteins dysregulation and cerebral inflammation in ketamine rat model of psychosis: role of GPR109A receptor","volume":"119","author":"Ibrahim","year":"2022","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.intimp.2026.117303_bb0180","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3390\/pharmaceutics13101635","article-title":"The tragedy of Alzheimer\u2019s disease: towards better management via resveratrol-loaded oral bilosomes","volume":"13","author":"Abbas","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.intimp.2026.117303_bb0185","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1007\/s10787-023-01269-y","article-title":"Cognitive enhancing effects of pazopanib in D-galactose\/ovariectomized Alzheimer\u2019s rat model: insights into the role of RIPK1\/RIPK3\/MLKL necroptosis signaling pathway","volume":"31","author":"Abdelhady","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.intimp.2026.117303_bb0190","series-title":"Handbook of Histopathological and Histochemical Techniques","author":"Culling","year":"2013"},{"issue":"1","key":"10.1016\/j.intimp.2026.117303_bb0195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11481-025-10231-4","article-title":"Sigma-1 receptor activation by fluvoxamine ameliorates ER stress, synaptic dysfunction and behavioral deficits in a ketamine model of schizophrenia","volume":"20","author":"Ahmed","year":"2025","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117303_bb0200","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.intimp.2026.117303_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110668","article-title":"The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: a systematic review and meta-analysis","volume":"121","author":"Patlola","year":"2023","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.intimp.2026.117303_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.714943","article-title":"Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2\/STAT3 pathway inhibition","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117303_bb0215","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae010","article-title":"PI3K-AKT\/mTOR signaling in psychiatric disorders: a valuable target to stimulate or suppress?","volume":"27","author":"Chen","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7435","key":"10.1016\/j.intimp.2026.117303_bb0220","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature11748","article-title":"Suppression of neuroinflammation by astrocytic dopamine D2 receptors via \u03b1B-crystallin","volume":"494","author":"Shao","year":"2013","journal-title":"Nature"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:35:45Z","timestamp":1790436945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":44,"alternative-id":["S1567576926011501"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117303","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baricitinib ameliorates behavioral deficits and NLRP3-related neuroinflammation in a ketamine rat model of schizophrenia: Role of JAK2\/STAT3 and PI3K\/AKT\/mTOR signaling","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117303"}}